Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, October 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,017 followers.

RT @JournalofExper1: 𝐍𝐞𝐰 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡! #BRD7 suppresses invasion and #metastasis in #breastcancer by negatively regulating YB1-induced epitheli…

𝐍𝐞𝐰 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡! #BRD7 suppresses invasion and #metastasis in #breastcancer by negatively regulating YB1-induced epithelial-mesenchymal transition. 𝐇𝐞𝐫𝐞 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 >>> https://t.co/CerrCHL3p7…/s13046-019-1493-4 https://t.co/qw7kaOT5x6

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovaria… http://t.co/Zuqu0jGnX8

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.